Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
ConclusionsSuvorexant treatment for insomnia of subjects with T2DM significantly improved CGM-measured daily glycemic control, which was associated with changes in sympathomimetic tone and/or improved insulin sensitivity. The amelioration of insomnia may therefore be a target for improving glycemic control in T2DM patients with insomnia.
Source: Journal of Clinical and Translational Endocrinology - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Insomnia | Insulin | Reflex Sympathetic Dystrophy | Sleep Disorders | Sleep Medicine